Multicenter, randomized, doubleblinded, placebo controlled, phase 3 trial of Fulvestrant (Faslodex) with or without PD0332991 (Palbociclib) Goserelin in women with hormone receptor positive, Her2 2 Negative metastatic breast cancer whose disease progressed after prior endocrine therapy